Business Context and Reporting Period
This Form 8-K Current Report from Phathom Pharmaceuticals, Inc. (PHAT) covers events occurring on March 31, 2025, and April 1, 2025. The filing primarily addresses a significant leadership transition at the executive level and the adoption of a new equity incentive plan.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- Executive Leadership Transition: Terrie Curran resigned as President, Chief Executive Officer, and Board member effective March 31, 2025, for personal reasons. Steven Basta was appointed as the new Chief Executive Officer, President, and Class I director effective April 1, 2025.
- New Equity Plan Adoption: The Board adopted the 2025 Employment Inducement Incentive Award Plan on March 30, 2025, reserving 2,500,000 shares of common stock for issuance without stockholder approval under Nasdaq rules.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, revenue outlook, or general management commentary regarding the company's strategic direction beyond the leadership change. However, it details specific compensation terms and risks associated with the new executive agreements:
- Steven Basta Compensation:
- Annual base salary: $700,000.
- Target annual bonus: 70% of base salary.
- Equity Grants: 1,085,000 stock options (4-year vesting), 360,000 performance stock units (PSUs) tied to stock price hurdles, and 180,000 PSUs tied to revenue targets through 2027.
- Severance: 15 months of salary and bonus upon termination without cause outside a change in control; 24 months and 2x bonus within a change in control period.
- Terrie Curran Severance:
- Salary continuation through June 30, 2026.
- Lump sum equal to 2025 target bonus.
- Accelerated vesting of time-based awards through June 30, 2026.
- Risks and Contingencies: The new equity plan is subject to Nasdaq listing rules regarding inducement awards. Executive severance benefits are contingent upon the execution of a release of claims and compliance with post-termination obligations.
Investor Verification Checklist
- Verify the filing of the Form S-8 registration statement for the 2025 Employment Inducement Incentive Award Plan to confirm the grant of Mr. Basta's equity awards.
- Review the specific revenue targets and stock price hurdles defined in the performance stock unit agreements for Mr. Basta.
- Confirm the final terms of the separation agreement with Ms. Curran once executed.
- Monitor future filings for the impact of the leadership transition on the company's operational strategy and clinical development pipeline.